{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:51:13Z","timestamp":1784951473296,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA33572"],"award-info":[{"award-number":["P30CA33572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008307","name":"Beckman Research Institute, City of Hope","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0331"],"award-info":[{"award-number":["W81XWH-22-1-0331"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-25-1-0500"],"award-info":[{"award-number":["HT9425-25-1-0500"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.tranon.2026.102751","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:14:43Z","timestamp":1775060083000},"page":"102751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Small but mighty: Peptides as next-generation immunotargeting agents in gynecological cancers"],"prefix":"10.1016","volume":"67","author":[{"given":"Pankaj","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6415-8160","authenticated-orcid":false,"given":"Sharad S.","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102751_bib0001","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1186\/s12889-021-10907-5","article-title":"Weiquing, trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC. Public Health"},{"issue":"3","key":"10.1016\/j.tranon.2026.102751_bib0002","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3892\/ol.2020.11754","article-title":"Cervical cancer in low and middle-income countries","volume":"20","author":"Hull","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.tranon.2026.102751_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1511560","article-title":"Expanding horizons of cancer immunotherapy: hopes and hurdles","volume":"15","author":"Sonar","year":"2025","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102751_bib0004","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jjco\/hyaa214","article-title":"Current status of cancer immunotherapy for gynecologic malignancies","volume":"51","author":"Nishio","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102751_bib0005","first-page":"107","article-title":"Aptamers and antibodies: rivals or allies in cancer targeted therapy?","volume":"2","author":"Agnello","year":"2021","journal-title":"Explor. Target. Anti-Tumor. Ther."},{"issue":"9","key":"10.1016\/j.tranon.2026.102751_bib0006","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.3390\/ijms21093252","article-title":"Aptamers and antisense oligonucleotides for diagnosis and treatment of hematological diseases","volume":"21","author":"Giudice","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.tranon.2026.102751_bib0007","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3390\/ijms23031445","article-title":"Bioactive peptides: synthesis, sources, applications, and proposed mechanisms of action","volume":"23","author":"Akbarian","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.102751_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1135523","article-title":"Peptides for diagnosis and treatment of ovarian cancer","volume":"13","author":"Guo","year":"2023","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102751_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103554","article-title":"Peptide modulators of cell migration: overview, applications and future development","volume":"28","author":"Gattringer","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tranon.2026.102751_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9749363","article-title":"Development of peptide-based vaccines for cancer","volume":"2022","author":"Abd-Aziz","year":"2022","journal-title":"J. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102751_bib0011","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2062982","article-title":"The progress of peptide vaccine clinical trials in gynecologic oncology","volume":"18","author":"Tang","year":"2022","journal-title":"Hum. Vaccin. ImmunOther"},{"issue":"13","key":"10.1016\/j.tranon.2026.102751_bib0012","doi-asserted-by":"crossref","first-page":"6833","DOI":"10.3390\/ijms25136833","article-title":"New insights into aptamers: an alternative to antibodies in the detection of molecular biomarkers","volume":"25","author":"Domsicova","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.tranon.2026.102751_bib0013","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/GRF.0000000000000513","article-title":"Immunotherapy for gynecologic cancer: current applications and future directions","volume":"63","author":"Lynam","year":"2020","journal-title":"Clin. Obstet. Gynecol."},{"issue":"7","key":"10.1016\/j.tranon.2026.102751_bib0014","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.3390\/biomedicines11072086","article-title":"Therapeutic targets of monoclonal antibodies used in the treatment of cancer: current and emerging","volume":"11","author":"Effer","year":"2023","journal-title":"Biomedicines."},{"key":"10.1016\/j.tranon.2026.102751_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1304342","article-title":"Antisense oligonucleotides: a novel frontier in pharmacological strategy","volume":"14","author":"Collotta","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102751_bib0016","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/2472630318816668","article-title":"siRNA-conjugated nanoparticles to treat ovarian cancer","volume":"24","author":"Halbur","year":"2019","journal-title":"SLAS. Technol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102751_bib0017","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.tranon.2026.102751_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1053984","article-title":"Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers","volume":"10","author":"Li","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102751_bib0019","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"issue":"17","key":"10.1016\/j.tranon.2026.102751_bib0020","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.3390\/cancers16172940","article-title":"Therapeutic antisense oligonucleotides in oncology: from bench to bedside","volume":"16","author":"\u00c7akan","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.tranon.2026.102751_bib0021","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the mechanisms and challenges of cancer drug resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.tranon.2026.102751_bib0022","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.tranon.2026.102751_bib0023","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tranon.2026.102751_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1135523","article-title":"Peptides for diagnosis and treatment of ovarian cancer","volume":"13","author":"Guo","year":"2023","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102751_bib0025","doi-asserted-by":"crossref","first-page":"e6800","DOI":"10.1002\/cam4.6800","article-title":"RGD peptide in cancer targeting benefits, challenges, solutions, and possible integrin-RGD interactions","volume":"13","author":"Javid","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.tranon.2026.102751_bib0026","doi-asserted-by":"crossref","first-page":"zyaf003","DOI":"10.1093\/intbio\/zyaf003","article-title":"Role of RGD-binding integrins in ovarian cancer progression, metastasis and response to therapy","volume":"17","author":"Ranga","year":"2025","journal-title":"Integr. Biol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102751_bib0027","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12935-022-02553-7","article-title":"Investigating the role of peptides in effective therapies against cancer","volume":"22","author":"Naeimi","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"6","key":"10.1016\/j.tranon.2026.102751_bib0028","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/0960-0760(90)90457-V","article-title":"LHRH-receptors and LHRH-agonist treatment in ovarian cancer: an overview","volume":"37","author":"Emons","year":"1990","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102751_bib0029","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.apsb.2022.07.020","article-title":"Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?","volume":"13","author":"Fu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.tranon.2026.102751_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188486","article-title":"Peptides that immunoactivate the tumor microenvironment","volume":"1875","author":"Furukawa","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.tranon.2026.102751_bib0031","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","article-title":"Peptides as multifunctional players in cancer therapy","volume":"55","author":"Vadevoo","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"11","key":"10.1016\/j.tranon.2026.102751_bib0032","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.3390\/jcm13113202","article-title":"CAR-T-cell-based cancer immunotherapies: potentials, limitations, and future prospects","volume":"13","author":"Choudhery","year":"2024","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.tranon.2026.102751_bib0033","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/14728214.2023.2218643","article-title":"Emerging peptide therapeutics for the treatment of ovarian cancer","volume":"28","author":"Veneziani","year":"2023","journal-title":"Expert. Opin. Emerg. Drugs"},{"issue":"21","key":"10.1016\/j.tranon.2026.102751_bib0034","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.3390\/molecules27217232","article-title":"Peptide-drug conjugates: a new hope for cancer management","volume":"27","author":"Chavda","year":"2022","journal-title":"Molecules."},{"issue":"1","key":"10.1016\/j.tranon.2026.102751_bib0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.tranon.2026.102751_bib0036","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3390\/ijms19061706","article-title":"High-risk Human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis","volume":"19","author":"Yeo-Teh","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.102751_bib0037","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.3389\/fimmu.2018.03000","article-title":"Antigenic peptide prediction from E6 and E7 oncoproteins of HPV types 16 and 18 for therapeutic vaccine design using immunoinformatics and MD simulation analysis","volume":"9","author":"Jabbar","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102751_bib0038","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.3802\/jgo.2019.30.e46","article-title":"Immunotherapy in endometrial cancer: new scenarios on the horizon","volume":"30","author":"Di Tucci","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.tranon.2026.102751_bib0039","article-title":"Peptide-based delivery of therapeutics in cancer treatment","volume":"14","author":"Samec","year":"2022","journal-title":"Mater. Today Bio."},{"issue":"5","key":"10.1016\/j.tranon.2026.102751_bib0040","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1002\/ctm2.822","article-title":"The role of cell-penetrating peptides in potential anti-cancer therapy","volume":"12","author":"Zhou","year":"2022","journal-title":"Clin. Transl. Med."},{"issue":"22","key":"10.1016\/j.tranon.2026.102751_bib0041","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3390\/cells13221869","article-title":"Clinical applications of antisense oligonucleotides in cancer: a focus on glioblastoma","volume":"13","author":"Khuu","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.tranon.2026.102751_bib0042","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3389\/fimmu.2017.01936","article-title":"Monoclonal antibody therapies for hematological malignancies: not just lineage-specific targets","volume":"8","author":"Cuesta-Mateos","year":"2018","journal-title":"Front. Immunol."},{"issue":"22","key":"10.1016\/j.tranon.2026.102751_bib0043","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.molcel.2021.09.002","article-title":"Oncogene-dependent sloppiness in mRNA translation","volume":"81","author":"Champagne","year":"2021","journal-title":"Mol. Cell"},{"issue":"13","key":"10.1016\/j.tranon.2026.102751_bib0044","doi-asserted-by":"crossref","first-page":"6833","DOI":"10.3390\/ijms25136833","article-title":"New insights into aptamers: an alternative to antibodies in the detection of molecular biomarkers","volume":"25","author":"Domsicova","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.tranon.2026.102751_bib0045","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1007\/s11033-023-08380-x","article-title":"Generation of peptides using phage display technology for cancer diagnosis and molecular imaging","volume":"50","author":"Pung","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.tranon.2026.102751_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2022.100125","article-title":"Advances in peptide-drug conjugate-based supramolecular hydrogel systems for local drug delivery","volume":"14","author":"Shang","year":"2022","journal-title":"Med. Drug Discov."},{"issue":"8","key":"10.1016\/j.tranon.2026.102751_bib0047","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3390\/vaccines12080950","article-title":"Advancements and challenges in peptide-based cancer vaccination: a multidisciplinary perspective","volume":"12","author":"Liu","year":"2024","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.tranon.2026.102751_bib0048","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3390\/vaccines13111150","article-title":"Shaping antitumor immunity with peptide vaccines: implications of immune modulation at the vaccine site","volume":"13","author":"Sarkar","year":"2025","journal-title":"Vaccines. (Basel)"},{"issue":"4","key":"10.1016\/j.tranon.2026.102751_bib0049","first-page":"274","article-title":"Neoantigen cancer vaccines: a new star on the horizon","volume":"21","author":"Li","year":"2023","journal-title":"Cancer Biol. Med."},{"issue":"9","key":"10.1016\/j.tranon.2026.102751_bib0050","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3390\/vaccines13090960","article-title":"Report: a multi-peptide vaccine targeting individual somatic mutations induces tumor infiltration of neoantigen-specific T cells in a patient with metastatic colorectal cancer","volume":"13","author":"Rabsteyn","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.tranon.2026.102751_bib0051","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2024.07.675","article-title":"& TPIV200 Ovarian cancer Study investigators (listed at the end) vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: a randomized, multicenter clinical trial","volume":"189","author":"Gupta","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102751_bib0052","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000829","article-title":"Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial","volume":"8","author":"Zamarin","year":"2020","journal-title":"J. ImmunOther Cancer"},{"issue":"11","key":"10.1016\/j.tranon.2026.102751_bib0053","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.3390\/pharmaceutics14112533","article-title":"Instability challenges and stabilization strategies of pharmaceutical proteins","volume":"14","author":"Akbarian","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tranon.2026.102751_bib0054","doi-asserted-by":"crossref","DOI":"10.1098\/rsfs.2017.0030","article-title":"Factors affecting the physical stability (aggregation) of peptide therapeutics","volume":"7","author":"Zapadka","year":"2017","journal-title":"Interface Focus."},{"issue":"6","key":"10.1016\/j.tranon.2026.102751_bib0055","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/1078-0432.CCR-21-2599","article-title":"U.S. FDA drug approvals for gynecological malignancies: a decade in review","volume":"28","author":"Arora","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.tranon.2026.102751_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110115","article-title":"Monoclonal antibody biosimilars for cancer treatment","volume":"27","author":"Broer","year":"2024","journal-title":"iScience"},{"issue":"10","key":"10.1016\/j.tranon.2026.102751_bib0057","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/biom14101303","article-title":"Future perspective: harnessing the power of artificial intelligence in the generation of new peptide drugs","volume":"14","author":"Nissan","year":"2024","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.tranon.2026.102751_bib0058","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.gce.2022.07.010","article-title":"Multi-functional engineered polypeptide-based drug delivery systems for improved cancer therapy","volume":"4","author":"Li","year":"2023","journal-title":"Green Chem. Eng."},{"issue":"6","key":"10.1016\/j.tranon.2026.102751_bib0059","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/14712598.2020.1729351","article-title":"Combination therapy with oncolytic viruses and immune checkpoint inhibitors","volume":"20","author":"Chiu","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.tranon.2026.102751_bib0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/pharmaceutics17010046","article-title":"Peptides as versatile regulators in cancer immunotherapy: recent advances, challenges, and future prospects","volume":"17","author":"Lei","year":"2025","journal-title":"Pharmaceutics"},{"issue":"13","key":"10.1016\/j.tranon.2026.102751_bib0061","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1021\/acs.jcim.4c00295","article-title":"Advancing peptide-based cancer therapy with AI: In-depth analysis of State-of-the-art AI models","volume":"64","author":"Bhattarai","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.tranon.2026.102751_bib0062","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10462-025-11148-3","article-title":"Bridging machine learning and peptide design for cancer treatment: a comprehensive review","volume":"58","author":"Rezaee","year":"2025","journal-title":"Artif. Intell. Rev."},{"issue":"8","key":"10.1016\/j.tranon.2026.102751_bib0063","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3390\/vaccines12080950","article-title":"Advancements and challenges in peptide-based cancer vaccination: a multidisciplinary perspective","volume":"12","author":"Liu","year":"2024","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.tranon.2026.102751_bib0064","doi-asserted-by":"crossref","first-page":"557","DOI":"10.18632\/oncotarget.297","article-title":"Targeting cancer with peptide aptamers","volume":"2","author":"Seigneuric","year":"2011","journal-title":"Oncotarget."},{"issue":"1","key":"10.1016\/j.tranon.2026.102751_bib0065","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40580-018-0170-1","article-title":"Peptide-nanoparticle conjugates: a next generation of diagnostic and therapeutic platforms?","volume":"5","author":"Jeong","year":"2018","journal-title":"Nano Converg."},{"issue":"3\u20134","key":"10.1016\/j.tranon.2026.102751_bib0066","first-page":"79","article-title":"The growing role of precision and personalized medicine for cancer treatment","volume":"6","author":"Krzyszczyk","year":"2018","journal-title":"Technol. Singap. World Sci."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326000884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326000884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:31:24Z","timestamp":1778833884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326000884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":66,"alternative-id":["S1936523326000884"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102751","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small but mighty: Peptides as next-generation immunotargeting agents in gynecological cancers","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102751"}}